Literature DB >> 34936106

In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery.

Zhonglei Wang1,2, Liyan Yang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34936106     DOI： 10.1002/jmv.27540

Source DB:  PubMed          Journal:  J Med Virol        ISSN： 0146-6615            Impact factor:   2.327


× No keyword cloud information.
  21 in total

Review 1.  Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.

Authors:  Queenie Fernandes; Varghese Philipose Inchakalody; Maysaloun Merhi; Sarra Mestiri; Nassiba Taib; Dina Moustafa Abo El-Ella; Takwa Bedhiafi; Afsheen Raza; Lobna Al-Zaidan; Mona O Mohsen; Mariam Ali Yousuf Al-Nesf; Ali Ait Hssain; Hadi Mohamad Yassine; Martin F Bachmann; Shahab Uddin; Said Dermime
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

Review 2.  Current Effective Therapeutics in Management of COVID-19.

Authors:  Kavya Atluri; Iris Aimlin; Shitij Arora
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

3.  Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators.

Authors:  Lorenza Fagnani; Lisaurora Nazzicone; Pierangelo Bellio; Nicola Franceschini; Donatella Tondi; Andrea Verri; Sabrina Petricca; Roberto Iorio; Gianfranco Amicosante; Mariagrazia Perilli; Giuseppe Celenza
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-04

Review 4.  Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19.

Authors:  Chengyu Liu; Wanyao Yan; Jiajian Shi; Shun Wang; Anlin Peng; Yuchen Chen; Kun Huang
Journal:  Front Nutr       Date:  2022-06-22

5.  Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue.

Authors:  Zhonglei Wang; Liyan Yang
Journal:  Front Public Health       Date:  2022-06-17

6.  Oral antivirals for the prevention and treatment of SARS-CoV-2 infection.

Authors:  Vicente Soriano; Carmen de-Mendoza; Benson Edagwa; Ana Treviño; Pablo Barreiro; José V Fernandez-Montero; Howard E Gendelman
Journal:  AIDS Rev       Date:  2022-03-01       Impact factor: 2.381

Review 7.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Authors:  Rekha Khandia; Shailja Singhal; Taha Alqahtani; Mohammad Amjad Kamal; Nahed A El-Shall; Firzan Nainu; Perumal Arumugam Desingu; Kuldeep Dhama
Journal:  Environ Res       Date:  2022-01-29       Impact factor: 8.431

Review 8.  The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.

Authors:  Alina Tanase; Aniko Manea; Alexandra Denisa Scurtu; Lavinia Melania Bratu; Doina Chioran; Alina Dolghi; Iren Alexoi; Hazzaa AAbed; Voichita Lazureanu; Cristina Adriana Dehelean
Journal:  Medicina (Kaunas)       Date:  2022-02-10       Impact factor: 2.430

9.  Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Authors:  Yuan-Pin Hung; Jen-Chieh Lee; Chun-Wei Chiu; Ching-Chi Lee; Pei-Jane Tsai; I-Lin Hsu; Wen-Chien Ko
Journal:  Antibiotics (Basel)       Date:  2022-02-09

Review 10.  Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.

Authors:  Yuan Zhang; Juhura G Almazi; Hui Xin Ong; Matt D Johansen; Scott Ledger; Daniela Traini; Philip M Hansbro; Anthony D Kelleher; Chantelle L Ahlenstiel
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.